Compare PLSE & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | ADNT |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2015 | 2016 |
| Metric | PLSE | ADNT |
|---|---|---|
| Price | $26.93 | $20.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $22.00 | ★ $25.41 |
| AVG Volume (30 Days) | 271.1K | ★ 954.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $17,439,000,000.00 |
| Revenue This Year | $840.00 | $2.71 |
| Revenue Next Year | $287.54 | $2.36 |
| P/E Ratio | ★ N/A | $338.17 |
| Revenue Growth | N/A | ★ 7.56 |
| 52 Week Low | $12.56 | $17.70 |
| 52 Week High | $28.53 | $27.32 |
| Indicator | PLSE | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 39.78 |
| Support Level | $23.94 | $20.23 |
| Resistance Level | $27.82 | $23.72 |
| Average True Range (ATR) | 1.71 | 0.95 |
| MACD | -0.03 | -0.26 |
| Stochastic Oscillator | 64.13 | 9.74 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.